Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation
Impact of a Quality Improvement And Education Initiative on 'Appropriate' Use of Anticoagulant Therapy in Patients With Atrial Fibrillation
Sponsor: Bristol-Myers Squibb
This NA trial investigates Atrial Fibrillation and Atrial Flutter and is currently completed. Bristol-Myers Squibb leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Study Description(click to expand)Setting - Cluster randomized trial. Setting - Primary care practices of an integrated healthcare system. Participants - 1,493 adults with non-valvular AF seen between April 2014 and March 2015.
Intervention - Treatment recommendations were made by an Atrial Fibrillation Decision Support Tool (AFDST) based on projections for quality-adjusted life expectancy calculated by a decision analytic model that integrates patient-specific risk factors for stroke and hemorrhage.
Setting - Cluster randomized trial. Setting - Primary care practices of an integrated healthcare system. Participants - 1,493 adults with non-valvular AF seen between April 2014 and March 2015.
Intervention - Treatment recommendations were made by an Atrial Fibrillation Decision Support Tool (AFDST) based on projections for quality-adjusted life expectancy calculated by a decision analytic model that integrates patient-specific risk factors for stroke and hemorrhage.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Oct 2022 — Dec 2022 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2022 [monthly]
Completed NA
-
Nov 2018 — Jan 2021 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status NA
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- National Center for Advancing Translational Sciences (NCATS)
- Pfizer
- University of Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .